Tonmya: Completed Phase III enrollment

Tonix completed enrollment of about 500 patients in the double-blind, placebo-controlled, U.S. Phase III AFFIRM trial evaluating 2.8 mg TNX-102 SL once daily at bedtime for 12 weeks. ...